Berenberg Bank began coverage on shares of BioNTech (NASDAQ:BNTX) in a report issued on Monday morning, Benzinga’s Daily Ratings Newsletter reports. The brokerage issued a buy rating and a $25.00 price objective on the stock.

Several other equities analysts have also commented on BNTX. UBS Group started coverage on BioNTech in a research note on Monday. They issued a buy rating and a $21.00 price target on the stock. JPMorgan Chase & Co. started coverage on BioNTech in a research note on Monday. They issued an overweight rating and a $23.00 price target on the stock. Svb Leerink started coverage on BioNTech in a research note on Monday. They issued an outperform rating on the stock. Canaccord Genuity started coverage on BioNTech in a research note on Monday. They issued a buy rating and a $22.00 price target on the stock. Finally, Bank of America started coverage on BioNTech in a research note on Monday. They issued a buy rating and a $21.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average price target of $22.17.

Shares of BioNTech stock traded up $0.45 during trading hours on Monday, hitting $18.87. The company’s stock had a trading volume of 78,100 shares, compared to its average volume of 321,229. BioNTech has a twelve month low of $12.52 and a twelve month high of $21.99.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer.

Read More: Understanding Market Liquidity

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.